214665 Finsbury WWP pp29-pp36 6 15 09 3:27 PM Page 33 Finsbury Worldwide Pharmaceutical Trust PLC Annual Report 2009 33 Income Statement for the year ended 31 March 2009 2009 2009 2009 2008 2008 2008 Revenue Capital Total Revenue Capital Total Notes 000 000 000 000 000 000 Gains losses on investments held at fair value through profit or loss 9 76,505 76,505 16,666 16,666 Exchange losses gains on currency balances 12,042 12,042 1,332 1,332 Income from investments held at fair value through profit or loss 2 4,018 4,018 3,404 3,404 Investment management, management and and performance fees 3 116 2,436 2,552 122 2,323 2,445 Other expenses 4 588 588 708 708 Net return loss before finance charges and taxation 3,314 62,027 65,341 2,574 17,657 15,083 Finance charges 5 29 543 572 51 976 1,027 Net return loss on ordinary activities before taxation 3,285 61,484 64,769 2,523 18,633 16,110 Taxation on net return loss on ordinary activities 6 866 360 506 782 372 410 Net return loss on ordinary activities after taxation 2,419 61,844 64,263 1,741 18,261 16,520 Return loss per share basic 7 5.5p 141.4p 146.9p 3.5p 37.1p 33.6p Return loss per share diluted 7 5.4p 138.2p 143.6p 3.5p 37.1p 33.6p The Total column of this statement is the Income Statement of the Company.
The Revenue and Capital columns are supplementary to this and are prepared under guidance published by the Association of Investment Companies.
All revenue and capital items in the above statement derive from continuing operations.
The Company has no recognised gains and losses other than those disclosed in the Income Statement and Reconciliation of Movements in Shareholders Funds.
Accordingly no separate Statement of Total Recognised Gains and Losses has been presented.
No operations were acquired or discontinued in the year.
The accompanying notes are an integral part of this statement.
